Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy As Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell Lymphomas
Year: 2012
Type: article
Study design: Clinical Trial
Source: Blood
Institutions: The University of Texas MD Anderson Cancer Center, University of Washington Medical Center, University of Alabama at Birmingham, Washington University in St. Louis, Stanford Medicine, Stanford University, Fox Chase Cancer Center, City Of Hope National Medical Center, University Hospital Southampton NHS Foundation Trust, The Christie Hospital, Seagen (United States), Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2559729686